Inquirer on MSN10d
World’s first anti-depression nasal spray receives FDA approvalThe US Food and Drug Administration (FDA) approved the first-ever anti-depression nasal spray, Spravato. The pharmaceutical ...
cbc.ca on MSN11d
'It changed my life tremendously': P.E.I.'s new ketamine clinic could offer mental health helpKetamine has been used as an anesthetic before surgeries for decades, but it can also be an option for those struggling with ...
The US Food and Drug Administration (FDA) has approved the use of esketamine nasal spray as a standalone treatment for adults with major depressive disorder (MDD) who have not responded adequately ...
In a Phase IIb trial, GH001 elicited significant drops in treatment-resistant depression. The news comes less than two weeks ...
The US Food and Drug Administration (FDA) has approved a supplemental new drug application allowing esketamine nasal spray (Spravato; Johnson & Johnson) to be used as a standalone treatment in ...
Share on Pinterest The FDA has approved an esketamine nasal spray for the treatment of depression cases that do not respond to other therapeutic approaches. Image credit: Koldunov/Getty Images.
Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven't responded to oral antidepressants.
Health Canada approved a prescription esketamine nasal spray called Spravato in 2020 to help with treatment-resistant depression. Brandi Martin, a nurse practitioner at NuVista, holds the device used ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback